Assembly Biosciences (NASDAQ:ASMB) announces that it has regained global rights to all microbiome gastrointestinal (GI) programs out-licensed to AbbVie (NYSE:ABBV) unit Allergan in January 2017. Its decision was not based on efficacy or safety issues.
The transition, expected to be completed in Q4, includes Phase 1-stage ABI-M201 and preclinical-stage ABI-M301.
The company says the event will not change its projected cash runway, expected to be sufficient to fund operations into 2022.
https://seekingalpha.com/news/3584322-abbvie-nixes-microbiome-gi-program-collaboration-assembly-biosciences
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.